Agilent Technologies is a high-quality franchise with a wide economic moat and strong margins, currently experiencing a near-term technical pause that has left growth priced attractively, with approximately 10.5% headroom to the take-profit target and a favorable risk/reward of roughly 1.6-to-1.
Thesis pillars
- Wide Moat Quality Franchise→Stable
- Growth At Reasonable Price→Stable
- Momentum Weakness Temporary Headwind↑Improving
- +1 more pillar — see the Why tab for full reasoning
Agilent Technologies, Inc. (A) Stock Analysis
Healthcare · Diagnostics & Research
Wait for pullback to $125.41. Recent C-suite change — blocks BUY_NOW at $148.53. Engine's entry $125.41 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Overbought (RSI 76).
Agilent Technologies makes instruments, software, services, and consumables for life sciences, diagnostics, and applied market laboratory workflows through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. With approximately 18,100... Read more
Wait for pullback to $125.41. Recent C-suite change — blocks BUY_NOW at $148.53. Engine's entry $125.41 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Overbought (RSI 76). Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.32, quality 7.6/10, growth 7.5/10). Score 6.0/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news boost analyst 0.70, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Agilent Technologies, Inc.
About Agilent Technologies, Inc.
Agilent Technologies offers instruments, software, services, and consumables spanning the full laboratory workflow across three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Approximately 18,100 employees as of October 31, 2025 serve over 22,200 customers in the Life Sciences segment, with primary manufacturing sites in nine countries. International operations represent the majority of total revenue.
Agilent earns revenue through capital instrument sales, consumables, and recurring service contracts. The CrossLab segment spans the entire lab with vendor-neutral consumables — chromatography columns, sample preparation products, custom chemistries — plus repairs, maintenance, compliance support, and software-as-a-service subscriptions that generate recurring revenues complementary to one-time capital purchases. The Life Sciences and Diagnostics Markets segment includes a specialty CDMO business (BIOVECTRA) that manufactures nucleic acid-based active pharmaceutical ingredients under pharmaceutical GMP conditions, serving customers advancing oligonucleotide therapies from clinical to commercial scale. Named competitors include AB Sciex (a Danaher division), Thermo Fisher Scientific, Bruker, and Waters Corporation. Products are sold primarily through direct sales, with resellers, distributors, and e-commerce supplementing coverage.
Show full overview
Agilent's companion diagnostic portfolio and FDA-registered manufacturing sites in California, Colorado, Texas, Vermont, Canada, Denmark, and Germany expose the Life Sciences segment to dual regulatory risk: companion diagnostic approvals are tied to partner pharmaceutical programs, meaning a clinical trial failure at a pharma partner could eliminate expected diagnostic revenue. Tariffs on goods from China and retaliatory measures by China on U.S. goods may weigh on instrument sales and supply chains, and inadequate federal agency funding could reduce demand from government research customers that rely on federal appropriations.
See also: Healthcare · Diagnostics & Research
From Agilent Technologies, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-08-16Recent Developments — Agilent Technologies, Inc.
Latest news
- NEWS Agilent Technologies (A) Could Be 14% Undervalued Following FDA Cancer Test Approval - Sahm — Sahm positive
- NEWS A|Agilent Technologies Inc|Price:138.160|Chg%:-2.140 - TradingKey — TradingKey negative
- NEWS A|Agilent Technologies Inc|Price:138.160|Chg%:-2.140 - tradingkey.com — tradingkey.com neutral
- NEWS Agilent Technologies (A) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Stocks making the biggest moves after hours: Snowflake, Marvell Technology, Agilent Technologies & more - CNBC — CNBC neutral
Generated 2026-08-16T18:17:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicinternational operations10-K Item 1A: 'revenue from international operations will continue to represent a majority of our total revenue'
Material Events(8-K, last 90d)
- 2026-04-06Item 5.02MEDIUMAgilent filed 8-K/A correcting EDGAR header of March 31, 2026 filing. Bret DiMarco (SVP, CLO, Secretary) entered transition agreement; will resign upon start of new CLO or by September 30, 2026. No immediate successor named at time of agreement.SEC filing →
- 2026-05-04Item 5.02MEDIUMMichael Buckner appointed as Chief Legal Officer of Agilent Technologies effective May 4, 2026. Bret DiMarco resigned as SVP, CLO, and Secretary; will remain as Special Advisor through December 1, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $125.41. Recent C-suite change — blocks BUY_NOW at $148.53. Engine's entry $125.41 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Overbought (RSI 76). Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.32, quality 7.6/10, growth 7.5/10). Target $170.81 (+15.0%), stop $118.87 (−25.0%), A.R:R -0.2:1. Score 6.0/10, moderate confidence.
Take-profit target: $170.81 (-3.0% upside). Target $170.81 (+15.0%), stop $118.87 (−25.0%), A.R:R -0.2:1. Stop-loss: $118.87.
Analyst target reached - limited upside remaining; Overbought (RSI 76).
Agilent Technologies, Inc. trades at a P/E of 29.8 (forward 22.5). TrendMatrix value score: 4.5/10. Verdict: Buy (Wait for Entry).
29 analysts cover A with a consensus score of 4.0/5. Average price target: $160.
What does Agilent Technologies, Inc. do?Agilent Technologies makes instruments, software, services, and consumables for life sciences, diagnostics, and applied...
Agilent Technologies makes instruments, software, services, and consumables for life sciences, diagnostics, and applied market laboratory workflows through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. With approximately 18,100 employees, the company sells to pharmaceutical, clinical, academic, and industrial customers worldwide, with international operations representing the majority of total revenue.